Jazz Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Jazz Pharmaceuticals is Bruce Cozadd, benoemd in Jan2003, heeft een ambtstermijn van 21.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 17.33M, bestaande uit 6.9% salaris en 93.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.69% van de aandelen van het bedrijf, ter waarde MX$ 791.57M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.6 jaar en 11.3 jaar.

Belangrijke informatie

Bruce Cozadd

Algemeen directeur

US$17.3m

Totale compensatie

Percentage CEO-salaris	6.9%
Dienstverband CEO	21.3yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	4.6yrs
Gemiddelde ambtstermijn bestuur	11.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bruce Cozadd's beloning veranderd ten opzichte van Jazz Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	US$415m
Sep 30 2023	n/a	n/a	US$80m
Jun 30 2023	n/a	n/a	-US$87m
Mar 31 2023	n/a	n/a	-US$156m
Dec 31 2022	US$17m	US$1m	-US$224m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$52m
Mar 31 2022	n/a	n/a	-US$450m
Dec 31 2021	US$16m	US$1m	-US$330m
Sep 30 2021	n/a	n/a	-US$161m
Jun 30 2021	n/a	n/a	US$40m
Mar 31 2021	n/a	n/a	US$518m
Dec 31 2020	US$13m	US$1m	US$239m
Sep 30 2020	n/a	n/a	US$179m
Jun 30 2020	n/a	n/a	US$133m
Mar 31 2020	n/a	n/a	US$280m
Dec 31 2019	US$15m	US$1m	US$523m
Sep 30 2019	n/a	n/a	US$609m
Jun 30 2019	n/a	n/a	US$656m
Mar 31 2019	n/a	n/a	US$486m
Dec 31 2018	US$11m	US$979k	US$447m
Sep 30 2018	n/a	n/a	US$520m
Jun 30 2018	n/a	n/a	US$434m
Mar 31 2018	n/a	n/a	US$447m
Dec 31 2017	US$10m	US$950k	US$488m

Compensatie versus markt: De totale vergoeding ($USD 17.33M ) Bruce } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 2.41M ).

Compensatie versus inkomsten: De vergoeding van Bruce is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bruce Cozadd (59 yo)

21.3yrs

Tenure

US$17,325,618

Compensatie

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board at January 2023. He served as Member of Board of Advisors at Cellares Co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bruce Cozadd	Co-Founder	21.3yrs	US$17.33m	0.69% MX$ 791.6m
Reneé Galá	President & COO	less than a year	US$5.03m	0.027% MX$ 30.7m
Robert Iannone	Executive VP and Global Head of Research & Development	4.9yrs	US$4.86m	0.045% MX$ 51.8m
Philip Johnson	Executive VP & CFO	less than a year	geen gegevens	0.019% MX$ 22.1m
Patricia Carr	Senior VP & Chief Accounting Officer	4.7yrs	geen gegevens	geen gegevens
Andrea Flynn	VP & Head of Investor Relations	no data	geen gegevens	geen gegevens
Neena Patil	Executive VP & Chief Legal Officer	4.8yrs	US$3.21m	0.026% MX$ 29.4m
Heidi Manna	Executive VP & Chief People Officer	5.4yrs	geen gegevens	geen gegevens
Jed Black	Senior Vice President of Sleep & CNS Medicine	no data	geen gegevens	geen gegevens
Samantha Pearce	Senior Vice President of Europe & International	4.1yrs	geen gegevens	0.023% MX$ 26.2m
John Miller	Senior Vice President of Corporate Strategy	4.6yrs	geen gegevens	geen gegevens
Mary Henderson	Senior Vice President of Technical Operations	less than a year	geen gegevens	geen gegevens

4.6yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van JAZZ N wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bruce Cozadd	Co-Founder	21.3yrs	US$17.33m	0.69% MX$ 791.6m
Kenneth O'Keefe	Independent Director	20.3yrs	US$468.68k	0.042% MX$ 48.1m
Seamus Mulligan	Independent Director	12.3yrs	US$482.86k	1.88% MX$ 2.2b
Peter Gray	Independent Director	10.9yrs	US$489.46k	0.021% MX$ 23.9m
Norbert Riedel	Independent Director	10.9yrs	US$488.59k	0.017% MX$ 19.6m
Patrick Gerald Enright	Independent Director	14.8yrs	US$481.18k	0.029% MX$ 32.9m
Rick Winningham	Lead Independent Director	13.9yrs	US$522.11k	0.012% MX$ 13.6m
Jennifer Cook	Independent Non-Executive Director	3.3yrs	US$481.32k	0.0061% MX$ 7.0m
Catherine Sohn	Independent Director	11.8yrs	US$477.84k	0.019% MX$ 21.7m
Heather McSharry	Independent Director	10.9yrs	US$499.46k	0.022% MX$ 25.2m
Mark Smith	Independent Non-Executive Director	3.3yrs	US$472.11k	0.0061% MX$ 7.0m
Anne O'Riordan	Independent Director	5.2yrs	US$475.42k	0.015% MX$ 17.5m

11.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van JAZZ N zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.3 jaar).

Jazz Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024

Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Recent updates

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD)

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024

Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares.

Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors

Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index

Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024

Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab

Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024

Insufficient new directors

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting

Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023

Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw

Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca

Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023

Insider recently sold Mex$5.3m worth of stock

Full year 2022 earnings released: US$3.58 loss per share (vs US$5.52 loss in FY 2021)

Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Insider recently sold Mex$5.5m worth of stock

Independent Non-Executive Director recently sold Mex$1.3m worth of stock

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting

Independent Director recently sold Mex$20m worth of stock

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn)

Insider recently sold Mex$571k worth of stock

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.86 loss in 3Q 2021)

Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022

Jazz Pharmaceuticals plc to Report Q3, 2022 Results on Nov 09, 2022

Insider recently sold Mex$189k worth of stock

Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022

Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex Epidyolex (Cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures

Senior VP & Chief Accounting Officer recently sold Mex$488k worth of stock

Second quarter 2022 earnings released: EPS: US$0.56 (vs US$6.11 loss in 2Q 2021)

Jazz Pharmaceuticals plc Updates Earnings Guidance for the Year 2022

Jazz Pharmaceuticals plc to Report Q2, 2022 Results on Aug 03, 2022

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 28, 2022

Jazz Pharmaceuticals plc Presents Positive Data from Phase 2/3 Trial of Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma At the ASCO 2022 Annual Meeting

Senior VP & Chief Accounting Officer recently sold Mex$385k worth of stock

Jazz Pharmaceuticals plc Raises Financial Guidance for the Full Year 2022

Jazz Pharmaceuticals plc to Report Q1, 2022 Results on May 04, 2022

Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, Including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types